[18F]-FDG-PET metabolic phenotyping in idiopathic normal pressure hydrocephalus: visual and voxel-wise evidence across neurodegenerative phenotypes
Objective: To characterise FDG-PET metabolic phenotypes in idiopathic normal pressure hydrocephalus (iNPH) using integrated visual and voxel-wise analyses. Background: iNPH is a potentially treatable cause…Midbrain Hypometabolism in Idiopathic REM Sleep Behavior Disorder Detected by [18F]-FDG PET as a Potential Biomarker of Nigral degeneration
Objective: The aim of this study was to investigate whether midbrain hypometabolism can already be detected in iRBD patients using [18F]-FDG PET scans. Background: Parkinson’s…Visualization of Small Brainstem Nuclei With the Ultra-High Performance NeuroEXPLORER PET Camera: a Comparison Study Using 18F-AV133
Objective: To compare the performance of 18F-AV133 between NeuroEXPLORER (NX) and standard resolution Siemens Biography (mCT) positron emission tomography (PET) cameras in people with Parkinson's…Subregional Striatal Dopaminergic Deficits, Cerebral Hypoperfusion and Cognitive Impairment in Parkinson’s Disease
Objective: To investigate the associations of subregional striatal dopaminergic deficits with regional cerebral blood flow (CBF) and cognitive impairment in patients with Parkinson’s disease (PD).…Early Reduction in Cerebral Histamine 3 Receptor Expression in People with Huntington’s Disease: Results from the iMarkHD Study
Objective: To quantify histamine 3 receptor (H3R) expression using positron emission tomography (PET) in people with Huntington’s disease (PwHD) across different stages of disease progression.…R1 from 18PR04.MZ as a Proxy for Cerebral Blood Flow in Degenerative Parkinsonism: Comparison with 15O-H2O PET/CT.
Objective: To evaluate the relationship between R1 from 18PR04.MZ and CBF assessed by 15O-H2O PET/CT in patients with parkinsonian syndromes. Background: 18PR04.MZ is an effective…Baseline assessment of nigrostriatal integrity via VMAT2 PET in participants with Parkinson’s disease from the BIIB122/DNL151 LUMA Phase 2b study
Objective: Evaluate nigrostriatal integrity using vesicular monoamine transporter 2 (VMAT2) PET in participants with early-stage PD enrolled in the LUMA study. Background: LUMA is a…Metabolic-Structural Patterns Across Progressive Supranuclear Palsy Clinical Variants: a Multimodal PET-MRI Study
Objective: To characterize patterns of regional glucose hypometabolism on Fluorodeoxyglucose (FDG)-PET and structural atrophy on MRI across clinical variants of progressive supranuclear palsy (PSP). Background:…Evidence of Systemic and Neuro-Inflammation in Progressive Supranuclear Palsy: Insight from an Imaging-Inflammation Study
Objective: To investigate the role of Th17 pathway in systemic and central inflammation in PSP and to identify signatures of inflammation-induced neurodegeneration in PSP. Background:…Distinct FDG PET Metabolic Signatures and Dopaminergic Loss Across Multiple System Atrophy Subtypes
Objective: To delineate subtype‑specific metabolic networks in Multiple system atrophy (MSA) using FDG‑PET, and to examine how these patterns relate to striatal dopamine transporter (DAT)…
- 1
- 2
- 3
- …
- 40
- Next Page »